No Data
Summit Therapeutics Shares Are Trading Lower. The Company's Partner Akeso Received FDA Approval for Its PD-1 Monoclonal Antibody, Penpulimab-kcqx, in Combination With Cisplatin or Carboplatin and Gemcitabine. The FDA Also Approved Penpulimab-kcqx as a...
'Akeso Wins Chinese Approval For Cancer Drug Positioned To Rival Merck's Keytruda; Company Discloses Early Data Hinting At A Survival Benefit' - STAT News
Summit Extends Gains as Cancer Drug Outperforms BeiGene's Tevimbra
Jiangsu Hengrui Pharmaceuticals: Authorized revenue becomes the "accelerator" for performance.
Personnel, products, and research and development are gradually becoming Global.
The upfront payment for the new ADC drug has boosted revenue, Jiangsu Hengrui Pharmaceuticals' Q1 revenue increased by 20.14% year-on-year, and net income increased by 36.9% | Earnings Reports insights.
In Q1, Jiangsu Hengrui Pharmaceuticals' revenue increased by 20.14% year-on-year, net income attributable to the parent company increased by 36.9%, and net income after deductions increased by 29.35% year-on-year. The significant increase in net income was primarily due to the company receiving a $75 million upfront payment for external licensing.
Summit Therapeutics' Partner Akeso HARMONi-6/AK112-306 Phase 3 Trial Of Ivonescimab In Combination With Platinum-based Chemotherapy Compared With Tislelizumab Met Its Primary Endpoint Of Progression-Free Survival For Locally Advanced Or Metastatic...
